Adherence to K/DOQI practice guidelines for bone metabolism and disease

American Journal of Managed Care

Volumn 13, Issue 11, 2007, Pages 620-625

  Hoy, Tracey ^a   Fisher, Maxine ^a   Barber, Beth ^b   Borker, Rohit ^b   Stolshek, Brad ^b   Goodman, William ^b  

^a HEALTHCORE INC   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BONE DISEASE; BONE METABOLISM; CHRONIC KIDNEY DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL;

BONE AND BONES; BONE DISEASES; CALCIUM; DIET; DISEASE PROGRESSION; FEMALE; GUIDELINE ADHERENCE; HEALTH STATUS; HEALTH STATUS INDICATORS; HUMANS; INSURANCE CLAIM REVIEW; KIDNEY FAILURE, CHRONIC; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; NUTRITIONAL STATUS; PARATHYROID HORMONE; PHOSPHORUS; PRACTICE GUIDELINES AS TOPIC; QUALITY OF HEALTH CARE; RETROSPECTIVE STUDIES;

EID: 36148959739     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. US Renal Data System. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases; 2005.
2. Collins A, Li S, Gilbertson D, et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int. 2003;64(suppl 87):S24-S31.
3. Weiner D, Tabatabai S, Tighiouart H, et al. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis. 2006;48:392-401.
4. Khan S, Kazmi W, Abichandani R, Tighiouart H, Pereira BJ, Kausz AT. Health care utilization among patients with chronic kidney disease. Kidney Int. 2002;62:229-236.
5. Go A, Chertow G, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
6. Kobus G, Malyszko J, Mysyliwiec M. Cardiovascular risk factors in dialyzed patients [in Polish]. Pol Arch Med Wewn. 2004;112;1425-1431.
7. Locatelli F, Pozzoni P, Tenton F, del Vecchio L. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrol Dial Transplant. 2003;18(suppl 7):vii2-9.
8. Buccianti G, Baragetti I, Bamonti F, Furiani S, Dorighet V, Patrosso C. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J Nephrol. 2004;17:405-410.
9. Fabbian F, Benussi P, Cacici G, et al. Relationship between diabetes mellitus and degree of coronary artery disease in uraemic patients investigated with coronary angiography. Int J Artif Organs. 2003;26:196-199.
10. Qunibi WY. Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD). Kidney Int Suppl. June 2005;(95):S43-S50.
11. Suliman ME, Qureshi AR, Barany P, et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int. 2000;57:1727-1735.
12. Cases A, Vera M, Lopez Gomez JM. Cardiovascular risk in patients with chronic renal failure. Patients in renal replacement therapy [in Spanish]. Nefrologia. 2002;22(suppl 1):68-74.
13. Zoccali C. Cardiovascular risk in uraemic patients - is it fully explained by classical risk factors? Nephrol Dial Transplant. 2000;15:454-457.
14. Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis. 1997;29:496-502.
15. De Boer I, Gorodetskaya I, Young B, et al. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol. 2002;13:2762-2769.
16. Fajtova VT, Sayegh MH, Hickey N, et al. Intact parathyroid hormone levels in renal insufficiency. Calcified Tissue Int. 1995;57:329-335.
17. Reichel H, Deibert B, Schmidt-Gayk H, et al. Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant. 1991;6:162-169.
18. St John A, Thomas MB, Davies CP, et al. Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate renal failure. Nephron. 1992;61:422-427.
19. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005;16:1788-1793.
20. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131-2138.
21. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208-2218.
22. Marco MP, Craver L, Betriu A, Belart M, Fibla J, Fernández E. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int Suppl. June 2003;(85): S111-S114.
23. Rubel JR, Milford EL. The relationship between serum calcium and phosphate levels and cardiac valvular procedures in the hemodialysis population. Am J Kidney Dis. 2003;41:411-421.
24. Hsu CY, Cummings SR, McCulloch CE, et al. Bone mineral density is not diminished by mild to moderate chronic renal insufficiency. Kidney Int. 2002;61:1814-1820.
25. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39: S1-S266.
26. Kausz AT, Guo H, Pereira BJ, et al. General medical care among patients with chronic kidney disease: opportunities for improving outcomes. J Am Soc Nephrol. 2005;16:3092-3101.
27. Winkelmayer WC, Levin R, Avorn J, et al. The nephrologist's role in the management of calcium-phosphorus metabolism in patients with chronic kidney disease. Kidney Int. 2003;63:1836-1842.
28. Lenz O, Mekala DP, Patel DV, Fornoni A, Metz D, Roth D. Barriers to successful care for chronic kidney disease. BMC Nephrol. 2005; 6:11.